Various breast cancer cell lines, including estrogen-receptor (ER)-positive or negative or triple-negative breast cancer (TNBC) cells, have displayed a dose-dependent response to CBD (mostly with low IC50 values [17,21,22,23,24,25,26]). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.